PHARMACY

GSK to acquire Stiefel Labs to create specialist dermatology business

BY Alaric DeArment

LONDON Days after it announced a plan to combine its HIV business with that of Pfizer, GlaxoSmithKline said Monday that it will acquire another company to create a specialist business for developing skin medications.

GSK will acquire Stiefel Labs for $2.9 billion, as well as $400 million in debt that it will incur at the closing of the deal, and a further $300 million in cash depending on future performance. GSK will combine its existing dermatology business with that of Stiefel, which will continue to operate under the Stiefel name within GSK.

“As part of our strategy to grow and diversify GSK’s business, we are continuing to make new investments through targeted acquisitions,” GSK CEO Andrew Witty said. “This transaction will create a new world-leading, specialist dermatology business and re-energize our existing dermatology products.”

The British drug maker announced last week that it and Pfizer would spin off their HIV divisions and form a new company to develop and market HIV drugs. The Stiefel acquisiton comes amid a wave of large-scale acquisitions among drug companies, including Pfizer’s purchase of Wyeth, Merck & Co.’s acquisition of Schering-Plough and Roche’s acquisition of Genentech.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Vertex reports Q1 earnings

BY Alaric DeArment

CAMBRIDGE, Mass. Vertex Pharmaceuticals ended first quarter 2009 with $869 million in cash, cash equivalents and marketable securities, the company announced Thursday.

The company is conducting a phase 3 study of telaprevir, a protease inhibitor for treating hepatitis C in patients who have not received treatment or for whom other treatments have failed. In March, Vertex started a phase 2a trial of VX-809, a compound designed to treat cystic fibrosis, and it also plans to start trials for the investigational CF drug VX-770 in the United States and Europe.

“With our strong performance in the first quarter, we are well-positioned to drive forward key programs in hepatitis C and cystic fibrosis and to deliver on our 2009 financial projections outlined earlier this year,” Vertex president Matt Emmens said. “Our top priority is to execute on the telaprevir phase 3 program and to prepare for [a new drug application] filing for telaprevir in the second half of 2010.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Drug maker’s shares fall after HHS requests regulatory filing

BY Alaric DeArment

NEW YORK A Department of Health and Human Services request that companies bidding on a government contract to provide anthrax vaccines give a regulatory plan to the Food and Drug Administration in 15 days caused shares of one of the companies to fall by 5.5% in afternoon trading on Friday, according to published reports.

The Associated Press reported Thursday that PharmAthene submitted a regulatory filing saying that HHS did not provide sufficient information. The HHS request caused PharmAthene’s shares to fall by 15 cents, to $2.56.

The Annapolis, Md.-based company makes the anthrax vaccine SparVax.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?